Catheter-directed Thrombolytic Therapy for Limb Ischemia: Current Status and Controversies

Mahmood K. Razavi, David S. Lee, Lawrence V. Hofmann

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Absence of urokinase from the United States market for the past 4 years has resulted in increasing experience with other plasminogen activators in catheter-directed thrombolytic therapy. The differences in the pharmacologic properties and biologic behavior of these agents may translate into clinical outcomes that are distinct. Some of these manifestations can be predicted based on the existing large clinical trials in the acute myocardial infarction literature. However, because of the fundamental differences in techniques and thrombolytic regimens, extrapolation of the coronary data may not always predict the performance of these agents in peripheral catheter-directed fibrinolysis. In this article, the current status of the available lytic agents in the treatment of limb ischemia is reviewed.

Original languageEnglish (US)
Pages (from-to)1491-1501
Number of pages11
JournalJournal of Vascular and Interventional Radiology
Issue number12
StatePublished - Dec 2003

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Catheter-directed Thrombolytic Therapy for Limb Ischemia: Current Status and Controversies'. Together they form a unique fingerprint.

Cite this